Discover the Game-Changing Vaccine Ushering in a New Era of Cancer Treatment

On behalf of Defence Therapeutics Inc.

The mere mention of cancer sends a shiver down the spine.

It’s an indiscriminate invader, plaguing the young and the strong more frequently than ever.

Here’s a shocker: a recent BMJ Oncology study reveals an alarming 79% spike in cancer cases among young adults in just three decades.¹

When the cancer is treatable, it’s usually combated with a grueling battle with chemotherapy—endless months of recovery, a barrage of side effects like fatigue and nausea.

Cancer has plagued our existence for centuries and despite decades of research, few solutions to combat this deadly illness have emerged.

Until now.

Scientific advances are shining brightly in the darkest corners, heralding a new dawn in cancer treatment.

The last few years have witnessed landmark strides in cancer treatment research. Innovators are crafting ingenious strategies to outsmart cancer’s evasion tactics.

Forget the one-size-fits-all approach; we’re talking smart, targeted, and astoundingly effective strategies that are reshaping the battlefield.

It’s no wonder Big Pharma is betting billions of dollars on groundbreaking cancer developments.²

Forget the one-size-fits-all approach; we’re talking smart, targeted, and astoundingly effective strategies that are reshaping the industry.

Breaking News

Defence Therapeutics Key Platform Patent Accepted Broadly Covering Vaccine Technology

One company that is completely changing the game with its revolutionary cancer vaccines is Defence Therapeutics Inc. (CSE:DTC) (OTC:DTCFF) – a standout biotech company engineering next-generation cancer vaccines using its patented Accum® Technology.

A recent study published in the esteemed Cancer Science journal unveils that Defence Therapeutics’ (CSE:DTC) (OTC:DTCFF) Accum® not only completely destroys cancer cells but also bolsters the immune system to combat cancer.³

This is where the future unfolds.

With its US patented and versatile state-of-the-art Accum™ Technology, Defence Therapeutics (CSE:DTC) (OTC:DTCFF) zeroes in on the most challenging cancers.

In stark contrast to chemotherapy, which indiscriminately harms both healthy and cancerous cells, Accum® precisely targets only the diseased segments of cells and delivers treatments with 10x the efficiency of current (ADC) methods by:⁴

- - Directing more treatment to the right cells
  - Penetrating cellular barriers
  - Homing in on precise intracellular locations
  - Ensuring only the targeted areas receive treatment

In recognition of its groundbreaking achievements, Defence Therapeutics was recently featured on Viewpoint with Dennis Quaid (an acclaimed short-form series) to spotlight this critical mission.⁵

image7 Discover the Game-Changing Vaccine Ushering in a New Era of Cancer Treatment

Right now Defence Therapeutics (CSE:DTC) (OTC:DTCFF) is at a pivotal juncture: it’s shifting from the discovery phase to clinical trials, preparing for two Phase 1 clinical trials for its patented cancer vaccines and anti-cancer therapeutics.⁶

Now surging ahead, Defence Therapeutics is on the trajectory to file an Investigational New Drug (IND) application with the FDA.⁷

Defence Therapeutics has created something so powerful, its competitors will soon come begging for their help.

7 Compelling Reasons

To Put Defence Therapeutics on Your Watchlist (CSE:DTC) (OTC:DTCFF)

Revolutionary Patented Technology: Boasting a US-patented Accum® Technology platform, Defence Therapeutics Inc. (CSE:DTC) (OTC:DTCFF) stands out with its ability to enhance intracellular treatment delivery. This platform is not just a step forward—it’s a giant leap, potentially boosting the efficacy of Defence Therapeutics and its partners’ products by an astounding 10-20X.⁸

Dynamic Progress Across the Board: With its Accum® Technology, Defence Therapeutics isn’t just dipping its toes but diving deep into two pioneering programs in cancer therapy and treatment development, each marked by notable strides.

Impressive Intellectual Property Suite: With a global IP portfolio encompassing 7 unique patent families covering everything from ADCs and Vaccines to RNA, DNA, MSCs, mRNA, Delivery, Mixing, Linking, Gene Editing, and even CRISPR/Cas9, Defence Therapeutics (CSE:DTC) (OTC:DTCFF) is poised for expansive global licensing opportunities.

Strong Financial Foundations: Defence Therapeutics (CSE:DTC) (OTC:DTCFF) stands on a solid capital structure with 43 million shares outstanding. Notably, only 22-25% of these shares are trading in the float, hinting at a stable investment landscape.

Leadership with Proven Expertise: At the helm is a seasoned team, including luminaries like Dr. Moutih Rafei, an immuno-oncology authority, and Dr. Raimar Löbenberg, the mind behind the University of Alberta’s Drug Development and Innovation Centre. This leadership assures a comprehensive approach, spanning pre-clinical studies to regulatory compliance.

National Spotlight with Dennis Quaid: Defence Therapeutics Inc. (CSE:DTC) (OTC:DTCFF) has caught the national eye through its collaboration with the renowned “Viewpoint,” television show hosted by Dennis Quaid. Set to air across over 170 U.S. stations, this feature will broadcast Defence Therapeutic’s biotech breakthroughs.

Stellar Preclinical Triumphs: Defence Therapeutics (CSE:DTC) (OTC:DTCFF) isn’t just promising; it’s delivering. Its preclinical achievements are nothing short of extraordinary, boasting a 100% cure rate in pre-established Lymphoma and an 80% success rate in combating Melanoma.

Revolutionizing the Battle Against Cancer: The Rise of a Groundbreaking Solution

image4 Discover the Game-Changing Vaccine Ushering in a New Era of Cancer Treatment

The innovative leadership of Dr. Moutih Rafei makes Defence Therapeutics Inc. (CSE:DTC) (OTC:DTCFF) a force in biotech.

With its innovative ACCUM® platform, this startup is redefining the game.
ACCUM® enhances pharmaceutical potency 10-20 times. This represents a quantum leap in medicinal efficacy. On top of that, ACCUM® targets infected cells while preserving healthy ones, saving money and boosting efficacy.

Defence Therapeutics (CSE:DTC) (OTC:DTCFF) is different from other biotech companies. The company focuses on cancer, but its ACCUM® technology can fight a variety of infectious diseases.

Defense Therapeutics (CSE:DTC) (OTC:DTCFF) delivers outcomes, not just potential. Pancreatic and ovarian cancers are the company’s most difficult challenges, and early results are promising, with a 100% cure rate in lymphoma and 80% efficacy in melanoma. These aren’t simply numbers—they signal a medical breakthrough.

Defence Therapeutics is rethinking the fight against humanity’s biggest enemies in a field where life is at risk.

image5 Discover the Game-Changing Vaccine Ushering in a New Era of Cancer Treatment

And here’s the kicker: Defence Therapeutics (CSE:DTC) (OTC:DTCFF) isn’t hoarding its technology; rather, it’s willing to share. They are now in talks with multiple drug manufacturers about licensing their Accum® Technology to improve existing treatments or medications.

DTC Chart Discover the Game-Changing Vaccine Ushering in a New Era of Cancer Treatment

The clever use of ADCs (antibody-drug conjugates) is what makes Accum® Technology stand out. This is like a high-tech GPS for cancer drugs that helps them get right to the source of the problem.

Early tests are already showing that the use of this technology shows incredible potential in stopping tumor growth.

Fast-Tracking the Fight Against Cancer

Defence Therapeutics Inc. (CSE:DTC) (OTC:DTCFF) is charging ahead with a robust strategy to tackle some of today’s deadliest cancers. At the heart of the company’s arsenal is the ARM Vaccine—a breakthrough treatment crafted to train the immune system to spot and destroy malignant cancer cells.

image6 Discover the Game-Changing Vaccine Ushering in a New Era of Cancer Treatment

Defence Therapeutics (CSE:DTC) (OTC:DTCFF) is starting pivotal trials to treat pancreatic cancer, one of the deadliest cancers with a startling 78.9% mortality rate that accounts for 8.3% of all cancer deaths. The company is collaborating with Transbiotech Biotechnology Research, a pioneer in the Canadian biotech scene.⁹

The goal of the upcoming clinical trials is to combine the ARM Vaccine with another treatment to boost immunity and demonstrate the efficacy of this treatment when conventional medicines have failed.

With every step leading up to Phase I trials, Defence Therapeutics (CSE:DTC) (OTC:DTCFF) is making no exceptions. They want to petition Health Canada by the end of 2023, working with specialists to determine the most optimal dosing strategies and thoroughly testing the vaccine to guarantee its safety and effectiveness. If the regulatory authority gives their permission, they will enter two pivotal Phase I trials in 2024.

Watch this space for the results of the quality checks and preliminary drills, which should be available by spring of next year. Defence Therapeutics will be poised to obtain Health Canada’s approval and begin their Phase I clinical trial in 2024.

image1 Discover the Game-Changing Vaccine Ushering in a New Era of Cancer Treatment

Breakthrough Molecule Paving the Way for a New Era in Cancer Treatment

Defence Therapeutics (CSE:DTC) (OTC:DTCFF) is making headlines with its novel AccuTOX™ molecule, a new hope in the fight against cancer. This isn’t just another cancer treatment; it’s a game-changer in the fight against various types of cancer.

AccuTOX™ is a special compound designed to target and destroy cancer cells through various mechanisms. It’s like a smart bomb for cancer cells, causing a chain reaction that leads to their death, stressing them out, and directly damaging their DNA.

The results from animal models are impressive. AccuTOX™ has shown to control tumor growth and work effectively with other common cancer treatments to deliver a more powerful punch.

In a study involving animals with lung cancer, treatment with AccuTOX™ through the nose led to a 50% reduction in cancer nodules in just two weeks with only six doses.

Press Releases

Defence Therapeutics (CSE:DTC) (OTC:DTCFF) is now preparing for a Phase I clinical trial, which is the first big test in humans. They’ve optimized the AccuTOX™ dosing schedule and combined it with two immune therapies. The early results suggest that AccuTOX™ could be a top contender for treating a variety of solid tumors.

Defence Therapeutics is gearing up to start a Phase I clinical trial for AccuTOX™, focusing initially on melanoma.¹⁰ This significant leap forward is made possible through a strategic collaboration with Biopeptek Pharmaceuticals.

But the potential of AccuTOX™ extends beyond skin cancer. It has shown promising results against other cancer types, such as lymphoma and breast cancer, positioning it as a versatile weapon in cancer¹¹ treatment.

Defence Therapeutics (CSE:DTC) (OTC:DTCFF) also recently discovered a way to wrap AccuTOX™ in special nanoparticles, making it even more effective. This method could revolutionize cancer treatment by targeting tumors more precisely, reducing the dosage needed, and cutting down on side effects.¹²

Adding to the company’s accolades, the US government has granted Defence Therapeutics a patent, endorsing their technology’s potential to combat cancer and infectious diseases.¹³ This patent acts as a seal of approval, empowering the company to enhance the efficacy of vaccines, potentially making them work better, faster, and more affordably.

image8 Discover the Game-Changing Vaccine Ushering in a New Era of Cancer Treatment

The journey for AccuTOX™ is just beginning. Defence Therapeutics is expanding its applications and exploring its potential further.

This could be the start of a new chapter in cancer treatment, offering a simpler, more effective approach that could very well be the next big thing in the fight against this formidable foe.

A Powerhouse Backed by the Elite

Dive into the financial backbone of Defence Therapeutics Inc. (CSE:DTC) (OTC:DTCFF), and you’ll find a structure that’s as solid as they come.

image3 Discover the Game-Changing Vaccine Ushering in a New Era of Cancer Treatment

What makes this company attractive is that only 22-25% of its total shares are available for trading.

Why is this important? Well, most of the company’s shares are held by experienced and wealthy investors who really believe in the company’s success. They aren’t just looking to make a quick profit; they are in it for the long haul to see how the company performs over time.

And there’s more good news: The company has some strong partnerships that are not just on paper. These partnerships provide additional support and make the company even more competitive in the biotech industry. This company has the backing of some influential and successful people and partners, which could make this company a promising choice for those who can recognize a company with immense potential.

image2 Discover the Game-Changing Vaccine Ushering in a New Era of Cancer Treatment

Meet the Exceptional Leadership Team of Defence Therapeutics (CSE:DTC) (OTC:DCTFF)

Defence Therapeutics’ (CSE:DTC) (OTC:DTCFF) leadership team offers deep technical expertise and a proven track record of wealth creation. The DTC team includes:

Sébastien PlouffeCEO and Director

With 25 years in finance, Plouffe excels in capital markets and project growth. He’s been a VP Senior Investment Advisor at top Canadian firms like BMO and Canaccord, specializing in fundraising and capital management. His diverse expertise spans sectors like biotech and mining.

Dr. Moutih RafeiChief Scientific Officer and Director

An expert in immuno-oncology, Dr. Rafei focuses on cancer therapeutics, T-cell-based therapies and stem cell biology. He holds a PhD from McGill University and has pioneered treatments for severe illnesses. His impactful research has earned over 20 awards and includes numerous publications and patents.

Dr. Sarkis MeterissianDirector

Dr. Meterissian is a tenured Professor of Surgery and Oncology who directs the MUHC Breast Center. His research covers clinical and basic science in breast cancer. He’s collaborated on NSERC-funded projects and serves on various cancer research boards

Dr. Raimar LöbenbergDirector and Chairman

Dr. Löbenberg holds degrees in Pharmacy and Pharmaceutics and founded the Drug Development and Innovation Centre at the University of Alberta. His research focuses on medication delivery and lung disease treatments. He’s also served on various health advisory panels.

Joseph MeagherDirector, Chairman

Dr. Löbenberg holds degrees in Pharmacy and Pharmaceutics and founded the Drug Development and Innovation Centre at the University of Alberta. His research focuses on medication delivery and lung disease treatments. He’s also served on various health advisory panels.

In Focus: 8 Convincing Factors

That Make Defence Therapeutics (CSE:DTC) (OTC:DTCFF) Stand Out

Revolutionary Patented Tech: Defence Therapeutics‘ (CSE:DTC) (OTC:DTCFF) US-patented Accum® Technology is a game-changer, offering unparalleled intracellular medication delivery that could revolutionize cancer treatment, potentially amplifying product efficacy by 10-20X.

Trailblazing Progress: With two flagship programs leveraging Accum® Technology for cancer solutions, Defence Therapeutics is making significant strides in the biotech field.

Expanding Horizons and Pipeline: At the heart of Defence Therapeutics‘ growth is its patented Accum® Technology, fueling two dynamic programs focused on cancer therapy and treatment development, each showing remarkable progress.

Robust IP Fortress: Boasting 7 unique patent families, Defence Therapeutics‘ (CSE:DTC) (OTC:DTCFF) global IP portfolio spans critical areas like ADCs, Vaccines, RNA, DNA, MSCs, mRNA, Delivery, Mixing, Linking, Gene Editing, and CRISPR/Cas9, setting the stage for global licensing opportunities.

Financial Resilience: With a solid capital structure of 43 million shares, only 22-25% of which are in the trading float, Defence Therapeutics demonstrates financial stability, backed by the confidence of savvy accredited investors.

Expert Leadership: Steering the ship is a team of industry veterans, including immuno-oncology luminary Dr. Moutih Rafei and Dr. Raimar Löbenberg, founder of the University of Alberta’s Drug Development and Innovation Centre.

National Recognition: A collaboration with Dennis Quaid’s Viewpoint is catapulting Defence Therapeutics (CSE:DTC) (OTC:DTCFF) into the national spotlight, with their biotech innovations set to broadcast across 170+ U.S. stations starting September 18, 2023.

Stellar Research Results: Preclinical studies have been nothing short of spectacular, with Defence Therapeutics reporting a 100% cure rate for established Lymphoma and an 80% success rate against Melanoma.

To sum up, Defense Therapeutics Inc. (CSE:DTC) (OTC:DTCFF) is one of a kind in the biotech business. They are not only raising the bar for cancer care with their cutting edge Accum® Technology; they are redefining it. This company isn’t just going after the easy targets; they’re going after the big ones, too, like the hardest types of cancer.

Visit Defense Therapeutics‘ official website right away to stay up to date on what’s going on with this innovative company. Stay up to date on the newest discoveries and progress.

If you keep an eye on Defense Therapeutics Inc. (CSE:DTC) (OTC:DTCFF), you’ll be the first to know about how they’re changing the way they fight cancer and elevating the pharmaceutical industry stronger across the board.

Disclaimer

QUICK LINKS TO PREFERRED BROKERAGES

footnotes:
[1] https://globalnews.ca/news/9938796/cancer-cases-young-adults-study/ [2] https://www.mirror.co.uk/news/uk-news/dad-who-staring-death-face-30885572 [3] https://defencetherapeutics.com/accum-technology/ [4] https://defencetherapeutics.com/defences-innovative-therapeutics-are-featured-on-viewpoint-with-dennis-quaid/ [5] Toglenn, CC BY-SA 4.0 , via Wikimedia Commons [6] https://defencetherapeutics.com/defences-broad-and-versatile-accum-technology-platform-focus-on-cancer-therapeutics/ [7]https://tinyurl.com/pcx5ppw6 [8] https://defencetherapeutics.com/wp-content/uploads/2023/04/Q2-23_Defence-Therapeutics-IR-Deck.pdf [9] https://seer.cancer.gov/statfacts/html/pancreas.html [10] https://tinyurl.com/4u64sxcuhttps://tinyurl.com/4u64sxcu [11] https://defencetherapeutics.com/defences-successful-accutox-pre-clinical-efficacy-study-complete-ready-for-phase-i-and-filing/ [12] https://defencetherapeutics.com/wp-content/uploads/2023/04/Defence-Therapeutics-press-release_April_24_US_Patent_Granted_Family_2_Robic-1.pdf [13] https://ca.finance.yahoo.com/news/big-pharma-goes-shopping-biotech-145100817.html?guccounter=2 [14] https://www.bloomberg.com/news/articles/2023-07-28/biogen-to-expand-in-rare-diseases-with-7-3-billion-reata-deal [15] https://www.biopharmadive.com/news/eli-lilly-dice-deal-acquisition-oral-autoimmune-il-17/653332/ [16] https://www.biopharmadive.com/news/eli-lilly-dice-deal-acquisition-oral-autoimmune-il-17/653332/ [17] https://finance.yahoo.com/news/european-swedish-orphan-biovitrum-acquire-134738468.html [18] https://pharmashots.com/15229/gsk-to-acquire-bellus-health-for-20b

Disclosure:

1) The author of the Article, or members of the author’s immediate household or family, do not own any securities of the companies set forth in this Article. The author determined which companies would be included in this article based on research and understanding of the sector.

2) The Article was issued on behalf of and sponsored by, Defence Therapeutics Inc. Market Jar Media Inc. has or expects to receive from Defence Therapeutics Inc.’s Digital Marketing Agency of Record (Native Ads Inc.) up to one hundred ninety-six thousand and two hundred fifty US dollars for a duration of up to twelve (12) months or until budget exhaustion as dictated by Defence Therapeutics Inc.

3) Statements and opinions expressed are the opinions of the author and not Market Jar Media Inc., its directors or officers. The author is wholly responsible for the validity of the statements. The author was not paid by Market Jar Media Inc. for this Article. Market Jar Media Inc. was not paid by the author to publish or syndicate this Article. Market Jar has not independently verified or otherwise investigated all such information. None of Market Jar or any of their respective affiliates, guarantee the accuracy or completeness of any such information. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security. Market Jar Media Inc. requires contributing authors to disclose any shareholdings in, or economic relationships with, companies that they write about. Market Jar Media Inc. relies upon the authors to accurately provide this information and Market Jar Media Inc. has no means of verifying its accuracy.

4) The Article does not constitute investment advice. All investments carry risk and each reader is encouraged to consult with his or her individual financial professional. Any action a reader takes as a result of the information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Market Jar Media Inc.'s terms of use and full legal disclaimer as set forth here. This Article is not a solicitation for investment. Market Jar Media Inc. does not render general or specific investment advice and the information on PressReach.com should not be considered a recommendation to buy or sell any security. Market Jar Media Inc. does not endorse or recommend the business, products, services or securities of any company mentioned on PressReach.com.

5) Market Jar Media Inc. and its respective directors, officers and employees hold no shares for any company mentioned in the Article.

6) This document contains forward-looking information and forward-looking statements, within the meaning of applicable Canadian securities legislation, (collectively, “forward-looking statements”), which reflect management's expectations regarding Defence Therapeutics Inc.’s future growth, future business plans and opportunities, expected activities, and other statements about future events, results or performance. Wherever possible, words such as “predicts”, “projects”, “targets”, “plans”, “expects”, “does not expect”, “budget”, “scheduled”, “estimates”, “forecasts”, “anticipate” or “does not anticipate”, “believe”, “intend” and similar expressions or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved, or the negative or grammatical variation thereof or other variations thereof, or comparable terminology have been used to identify forward-looking statements. These forward-looking statements include, among other things, statements relating to: (a) revenue generating potential with respect to Defence Therapeutics Inc.’s industry; (b) market opportunity; (c) Defence Therapeutics Inc.’s business plans and strategies; (d) services that Defence Therapeutics Inc. intends to offer; (e) Defence Therapeutics Inc.’s milestone projections and targets; (f) Defence Therapeutics Inc.’s expectations regarding receipt of approval for regulatory applications; (g) Defence Therapeutics Inc.’s intentions to expand into other jurisdictions including the timeline expectations relating to those expansion plans; and (h) Defence Therapeutics Inc.’s expectations with regarding its ability to deliver shareholder value. Forward-looking statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, as of the date of this document including, without limitation, assumptions about: (a) the ability to raise any necessary additional capital on reasonable terms to execute Defence Therapeutics Inc.’s business plan; (b) that general business and economic conditions will not change in a material adverse manner; (c) Defence Therapeutics Inc.’s ability to procure equipment and operating supplies in sufficient quantities and on a timely basis; (d) the accuracy of budgeted costs and expenditures; (e) Defence Therapeutics Inc.’s ability to attract and retain skilled personnel; (f) political and regulatory stability; (g) the receipt of governmental, regulatory and third-party approvals, licenses and permits on favorable terms; (h) changes in applicable legislation; (i) stability in financial and capital markets; and (j) expectations regarding the level of disruption to as a result of CV-19. Such forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of Defence Therapeutics Inc. to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation: (a) Defence Therapeutics Inc.’s operations could be adversely affected by possible future government legislation, policies and controls or by changes in applicable laws and regulations; (b) public health crises such as CV-19 may adversely impact Defence Therapeutics Inc.’s business; (c) the volatility of global capital markets; (d) political instability and changes to the regulations governing Defence Therapeutics Inc.’s business operations (e) Defence Therapeutics Inc. may be unable to implement its growth strategy; and (f) increased competition.

Except as required by law, Defence Therapeutics Inc. undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future event or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. Neither does Defence Therapeutics Inc. nor any of its representatives make any representation or warranty, express or implied, as to the accuracy, sufficiency or completeness of the information in this document. Neither Defence Therapeutics Inc. nor any of its representatives shall have any liability whatsoever, under contract, tort, trust or otherwise, to you or any person resulting from the use of the information in this document by you or any of your representatives or for omissions from the information in this document.

7) Any graphs, tables or other information demonstrating the historical performance or current or historical attributes of Defence Therapeutics Inc. or any other entity contained in this document are intended only to illustrate historical performance or current or historical attributes of Defence Therapeutics Inc. or such entities and are not necessarily indicative of future performance of Defence Therapeutics Inc. or such entities.

8) Investing is risky. The information provided in this article should not be considered as a substitute for professional financial consultation. Users should be aware that investing in any form carries inherent risks, and as such, there is a possibility of losing some or all of their investment. The value of investments can fluctuate significantly within a short period, and investors must understand that past performance is not indicative of future results. Additionally, users should exercise caution as transactions involving investments may be irreversible, even in cases of fraud or accidental actions. It is crucial to acknowledge that rapidly evolving laws and technical issues can have adverse effects on the usability, transferability, exchangeability, and value of investments. Furthermore, users must be cognizant of potential security risks associated with their investment activities. Individuals are strongly encouraged to conduct thorough research, seek professional advice, and carefully evaluate their risk tolerance before engaging in any investment endeavors. Market Jar Media Inc. is neither an investment adviser nor a broker-dealer. The information presented on the website is provided for informative purposes only and is not to be treated as a recommendation to make any specific investment. No such information on PressReach.com constitutes advice or a recommendation.

PressReach

SEARCH FOR AN ARTICLE

PressReach

PressReach

Discover the Game-Changing Vaccine Ushering in a New Era of Cancer Treatment

Breaking News

Revolutionizing the Battle Against Cancer: The Rise of a Groundbreaking Solution

Fast-Tracking the Fight Against Cancer

Breakthrough Molecule Paving the Way for a New Era in Cancer Treatment

Press Releases

A Powerhouse Backed by the Elite

Meet the Exceptional Leadership Team of Defence Therapeutics (CSE:DTC) (OTC:DCTFF)

QUICK LINKS TO PREFERRED BROKERAGES

More News From This Company

Defence Therapeutics Inc.

Company News

Don't Hestitate! Get The Corporate Presentation Now

PLUS

PressReach

Breaking News

SUBSCRIBE FOR TRADING INSIGHTS AND ALERTS. STAY AHEAD.

Revolutionizing the Battle Against Cancer: The Rise of a Groundbreaking Solution

Fast-Tracking the Fight Against Cancer

Breakthrough Molecule Paving the Way for a New Era in Cancer Treatment

Press Releases

SUBSCRIBE FOR TRADING INSIGHTS AND ALERTS. STAY AHEAD.

A Powerhouse Backed by the Elite

Meet the Exceptional Leadership Team of Defence Therapeutics (CSE:DTC) (OTC:DCTFF)

SUBSCRIBE FOR TRADING INSIGHTS AND ALERTS. STAY AHEAD.

Get Money Saving Tips

QUICK LINKS TO PREFERRED BROKERAGES

More News From This Company

Defence Therapeutics Inc.

Company News

Don't Hestitate! Get The Corporate Presentation Now

PLUS

Get Money
Saving Tips